Talniflumate

Research use only, not for human use.

Talniflumate is a calcium-activated chloride channel (hCLCA1/mCLCA3) blocker that reduces mucin synthesis and releases in animal models and cell culture.

Talniflumate is a calcium-activated chloride channel (hCLCA1/mCLCA3) blocker that reduces mucin synthesis and releases in animal models and cell culture. It possesses anti-inflammatory actions via inhibition of Cox (cyclooxygenase) and inhibits Cl-/HCO3- exchange activity. It also increases survival in a cystic fibrosis mouse model of the distal intestinal obstructive syndrome.(In Vivo):Talniflumate (oral chow; 0.4 mg/g; 21 days) significantly increases CF mouse survival from 26 to 77%. It does not alter crypt goblet cell numbers or change intestinal expression of mCLCA3 but tends to decrease crypt mucoid impaction.

——

Talniflumate (oral chow; 0.4 mg/g; 21 days) significantly increases CF mouse survival from 26 to 77%. It does not alter crypt goblet cell numbers or change intestinal expression of mCLCA3 but tends to decrease crypt mucoid impaction. Animal Model:CF mice with distal intestinal obstructive syndrome (DIOS)Dosage:0.4 mg/g Administration:Oral chow; 21 days Result:Increased survival in a cystic fibrosis mouse model of distal intestinal obstructive syndrome.

Talniflumate

Others

Other Targets

hCLCA1/mCLCA3|COX|Cl-/HCO3- exchanger|GCNT3

——

——

66898-62-2

414.33

C21H13F3N2O4

>98% (HPLC)

In Vitro:?DMSO : 62.5 mg/mL (150.85 mM)

FC(F)(F)c1cccc(Nc2ncccc2C(=O)OC2OC(=O)c3ccccc23)c1

2-[[3-(Trifluoromethyl)phenyl]amino]-3-pyridinecarboxylic acid 1,3-dihydro-3-oxo-1-isobenzofuranyl ester

(-20℃)

With Ice Pack

≥ 2 years